Resiquimod hydrogel - Surge Therapeutics
Alternative Names: Resiquimod hydrogel; STM-416; STM-416p; STM0416 SURGERxLatest Information Update: 13 Jun 2024
At a glance
- Originator Surge Therapeutics
- Class Adjuvants; Antineoplastics; Antivirals; Imidazoles; Quinolones; Skin disorder therapies; Small molecules
- Mechanism of Action Immunostimulants; Interferon alpha stimulants; Toll-like receptor 7 agonists; Toll-like receptor 8 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Bladder cancer
Most Recent Events
- 13 Jun 2024 SURGE Therapeutics plans a phase I trial for Prostate Cancer (Adjuvant therapy) in September 2024 (NCT06450106)
- 18 Aug 2023 Chemical structure information added
- 22 Jun 2023 Phase-I/II clinical trials in Bladder cancer (Late-stage disease, Recurrent) in USA (Parenteral) (NCT05710848)